Wells Fargo Maintains Overweight on PerkinElmer, Raises Price Target to $205
Wells Fargo analyst Dan Leonard maintains PerkinElmer (NYSE:PKI) with a Overweight and raises the price target from $200 to $205.
PerkinElmer Confirms That Omicron Variant Does Not Impact SARS-CoV-2 Detection Capability Of Its RT-PCR Assays
PerkinElmer, Inc. (NYSE:PKI), a global leader committed to innovating for a healthier world, today announced that the performance of its SARS-CoV-2 RT-PCR assays are not impacted by the emergence of
Here’s How Much $100 Invested In PerkinElmer 10 Years Ago Would Be Worth Today
PerkinElmer (NYSE:PKI) has outperformed the market over the past 10 years by 11.05% on an annualized basis.
PerkinElmer Q3 Earnings, FY21 Guidance Beat Wall Street Expectations
PerkinElmer Inc’s (NYSE:PKI) Q3 revenues increased 21% Y/Y (12% organic) to $1.17 billion, beating the consensus of $1.04 billion. Diagnostics…
Wells Fargo Maintains Overweight on PerkinElmer, Raises Price Target to $200
Wells Fargo analyst Dan Leonard maintains PerkinElmer (NYSE:PKI) with a Overweight and raises the price target from $190 to $200.
PerkinElmer: Q3 Earnings Insights
PerkinElmer (NYSE:PKI) reported its Q3 earnings results on Tuesday, November 2, 2021 at 04:00 PM.
Here's what investors need to know about the announcement.
Recap: PerkinElmer Q3 Earnings
PerkinElmer (NYSE:PKI) reported its Q3 earnings results on Tuesday, November 2, 2021 at 04:00 PM.
Here's what investors need to know about the announcement.
Earnings Scheduled For November 2, 2021
Companies Reporting Before The Bell
• Thomson Reuters (NYSE:TRI) is expected to report quarterly earnings at $0.48 per share on revenue of $1.86 billion.
PerkinElmer And Honeycomb Biotechnologies Launch The HIVE scRNAseq Solution For Single-Cell Analysis
PerkinElmer, Inc. (NYSE:PKI) and Honeycomb Biotechnologies, Inc., announced today the commercial launch of the first of its kind HIVETM scRNAseq Solution for single-cell isolation and analysis. The HIVE solution
